Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873955 | 0.76 | MAPT (0.33) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| SCHEMBL13158755 | 0.75 | MAPT (0.39) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| SCHEMBL1149412 | 0.70 | MAPT (0.36) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| SCHEMBL872296 | 0.69 | — | — | |
| SCHEMBL872789 | 0.68 | LMNA (0.32) | SLC22A16MAPT | |
| SCHEMBL2706629 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL872025 | 0.67 | MAPT (0.48) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| SCHEMBL3696754 | 0.65 | MAPT (0.36) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| SCHEMBL3686616 | 0.65 | MAPT (0.36) | SLC22A16MAPTTSHRCHRM2CHRM4 | |
| SCHEMBL873291 | 0.65 | LMNA (0.34) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130202530-A1 | NOVEL RADIOTRACER | IMPERIAL COLLEGE (GB) | 2013-08-08 | — | — | US | claimed |
| EP-2619172-A2 | NOVEL RADIOTRACER | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | claimed |
| WO-2012040138-A2 | NOVEL RADIOTRACER | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | claimed |
| US-20130202530-A1 | NOVEL RADIOTRACER | IMPERIAL COLLEGE (GB) | 2013-08-08 | — | — | US | disclosed |
| EP-2619170-A2 | ISOTOPIC CARBON CHOLINE ANALOGS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| EP-2619171-A2 | NOVEL PRECURSOR | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| EP-2619172-A2 | NOVEL RADIOTRACER | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183239-A1 | ISOTOPIC CARBON CHOLINE ANALOGS | IMPERIAL COLLEGE (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130178653-A1 | NOVEL PRECURSOR OF RADIOLABELLED CHOLINE ANALOG COMPOUNDS | IMPERIAL COLLEGE (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012040151-A2 | ISOTOPIC CARBON CHOLINE ANALOGS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040133-A2 | NOVEL PRECURSOR | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012040138-A2 | NOVEL RADIOTRACER | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178653-A1 | NOVEL PRECURSOR OF RADIOLABELLED CHOLINE ANALOG COMPOUNDS | CHAT, CEPT1, SLC5A7 | SLC22A16 1482/4885MAPT 321/4885TSHR 1767/4885 |
| US-20130183239-A1 | ISOTOPIC CARBON CHOLINE ANALOGS | CEPT1, CHAT, CHKB | SLC22A16 591/4885MAPT 390/4885TSHR 2196/4885 |
| US-20130202530-A1 | NOVEL RADIOTRACER | CEPT1, SGMS1, SGMS2 | SLC22A16 724/4885MAPT 726/4885TSHR 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.